De Novo
Pathway
Class II
Device Class
II/Non-Serious
SaMD Category
2/8
Standards Done
4
Standards Active
Q2 2027
Target Auth.
18-Month Submission Timeline
M1
M2
M3
M4
M5
M6
M7
M8
M9
M10
M11
M12
M13
M14
M15
M16
M17
M18
Pre-Submission
Preparation
Submission
FDA Review
Authorization
Post-Market
Standards Compliance Matrix
| Standard | Title | Classification | Progress | Status |
|---|---|---|---|---|
| IEC 62304:2006+AMD1:2015 | Software Lifecycle | Class B | 62% | active |
| IEC 62366-1:2015 | Usability Engineering | Required | 35% | active |
| ISO 14971:2019 | Risk Management | Required | 55% | active |
| IEC 60601-1:2005+AMD2 | Electrical Safety | Class I | 100% | complete |
| IEC 60601-1-2:2014 | EMC | Required | 0% | pending |
| FDA SaMD Guidance 2019 | SaMD Clinical Evidence | N/A | 48% | active |
| HIPAA Security Rule | PHI Protection | Required | 100% | complete |
| FDA MDR 21 CFR 803 | Mandatory Reporting | Class II | 5% | pending |
Clinical Evidence Requirements
✓
Analytical study — CFAR algorithm validation
2,400 radar frames, 100 scripted fall events; sens 94%, spec 94%
✓
Benchtop study — Range & angle accuracy
IWR6843AOP at 1 Hz, 4.5 m range, ±15° azimuth — PASS
●
Clinical pilot — MOH 36-unit deployment
ODAT-funded; IRB pending; 90-day study, 12 residents
Comparative study vs. EarlySense
Parallel deployment in 6 rooms, 30 days; planned post-pilot
Post-market study — real-world fall events
n=200 fall events across ≥3 facilities; 12-month collection
Predicate Device Comparison